Document is current
Any future updates will be listed below
-
Authors
Neubert, Sven
Munawar, Umair https://orcid.org/0000-0001-9710-9923
Mersi, Julia
Noderer, Julia
Nerreter, Silvia
Kurian, Shilpa
Han, Seungbin
Verbruggen, Christina https://orcid.org/0009-0004-4162-2188
Besant, Emma
Rein, Nina
Köppel, Max
Lehmann, Johanna
Köhler, Tabea
Labinsky, Hannah
Häusl, Sigrun
Tamamushi, Yoko
Zhou, Xiang
Pinter, Jule
Herzog, Anna Laura
Lopau, Kai
Hoxha, Elion
Rummelt, Christoph https://orcid.org/0000-0002-6471-7030
Gerhard-Hartmann, Elena
Rosenwald, Andreas
Steinbrunn, Torsten https://orcid.org/0000-0002-8793-9998
Nerreter, Thomas https://orcid.org/0000-0002-0493-1369
Hudecek, Michael https://orcid.org/0000-0002-2280-2202
Einsele, Hermann https://orcid.org/0000-0002-7680-0819
Rasche, Leo https://orcid.org/0000-0002-9536-9649
Kortüm, K. Martin https://orcid.org/0000-0002-7011-0286
Waldschmidt, Johannes M. https://orcid.org/0000-0001-5340-1818
-
Funding
Funding for this research was provided by:
Bundesministerium für Bildung und Forschung
Deutsche Forschungsgemeinschaft (TRR 387/1 – 514894665, TRR 387/1 – 514894665, 442740310, TRR 387/1 – 514894665, KFO 50001)
Deutsche Krebshilfe
Stifterverband
- License Information
-
More Information
Article History
Received: 6 August 2025
Revised: 7 August 2025
Accepted: 28 August 2025
First Online: 10 September 2025
Competing interests
: The authors declare the following competing interests: JMW reports personal fees from Janssen, Sanofi, Takeda, Pfizer, Oncopeptides, Menarini-Stemline, Skyline Dx and GSK, and research support from BMS. KMK reports personal fees from Celgene, BMS, AbbVie, GSK, and Takeda; grants and personal fees from Janssen. HE reports grants and other support from Janssen, BMS, Amgen, GSK, and Sanofi, as well as further support from Takeda and Novartis. LR reports personal fees from BMS, Janssen, Pfizer, Amgen, GSK and Sanofi. All other authors declare no competing interests.
